Events Archives - Page 28 of 128

3 minute read

Adagene Presents Data Demonstrating The Best-In-Class Therapeutic Index For Masked Anti-CTLA-4 SAFEbody ADG126 At SITC 2023

November 3, 12:07 PM

- MSS CRC case examples reinforce optimal dosing regimen in ongoing phase 2 dose expansion, with a confirmed partial response at ADG126 10 mg/kg every three weeks plus pembrolizumab – - Integrated pharmacokinetic

ADAG

3 minute read

Allogene Therapeutics Presents Preclinical Data On Next Generation Cloak And Dagger Technologies At The Society For Immunotherapy Of Cancer Annual Meeting

By Benzinga Newsdesk

November 3, 12:05 PM

Cloak™ and Dagger™ Technologies Show Potential to Reduce Dependence on Standard Lymphodepletion and Enhance Performance of AlloCAR T™ CellsData from Preclinical Study of Cloak™ Technology

ALLO

2 minute read

Allogene Therapeutics Presents Preclinical Data On A Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 At The Society For Immunotherapy Of Cancer Annual Meeting

By Benzinga Newsdesk

November 3, 12:05 PM

Research Provides Early Validation of ALLO-182, an AlloCAR T™ Candidate in the IND-Enabling Phase of Development Targeting Claudin18.2 for the Treatment of Patients with Gastric and Pancreatic CancersSOUTH SAN

ALLO

7 minute read

Cue Biopharma Presents New Data From Phase 1 Trials Of CUE-101 In Head and Neck Cancer And CUE-102 In Wilms’ Tumor 1 Positive Cancers At SITC 2023

By Benzinga Newsdesk

November 3, 12:04 PM

Overall response rate (ORR) of 47% and disease control rate (DCR) of 65% in first line (1L) recurrent/metastatic HNSCC patients treated with CUE-101 and KEYTRUDA® (pembrolizumab)ORR of 56% in patients with low

CUE

1 minute read

RAPT Therapeutics Announces Data, Including Objective Response Rates And Progression-Free Survival, From Its Phase 2 Trial Of FLX475 In Combination With A Checkpoint Inhibitor In Patients With Advanced NSCLC

By Benzinga Newsdesk

November 3, 12:03 PM

- Confirmed objective response rate (ORR) of 40% in PD-L1 positive (TPS ≥1%) patients with no prior checkpoint inhibitor therapy (CPI) - Median progression-free survival (PFS) of 6.3 months in PD-L1 positive

RAPT

2 minute read

BioCryst And Clearside Biomedical Enter Partnership To Develop Avoralstat For Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector; SCS Microinjector Is The First And Only FDA-Approved Approach To Access The Suprachoroidal Space

By Benzinga Newsdesk

November 3, 12:02 PM

– SCS Microinjector is the first and only FDA-approved approach to access the suprachoroidal space – – BioCryst to host R&D Day today at 1:00 pm ET –ALPHARETTA, Ga. and RESEARCH TRIANGLE PARK, N.C., Nov. 03,

BCRX

2 minute read

Events
News

Dolphin Entertainment Commends Special Projects For Exemplary Work At Town & Country’s 10th Annual Philanthropy Summit

By Benzinga Newsdesk

November 3, 9:16 AM

Special Projects, the leading agency in talent booking, creative content, and event production and a wholly-owned subsidiary of Dolphin Entertainment, Inc. (NASDAQ:DLPN), marked its ongoing collaboration as the Talent

DLPN

5 minute read

Aurinia Presents Breadth Of Data At ASN 2023 Demonstrating Clinical Importance Of LUPKYNIS For Managing Lupus Nephritis

By Benzinga Newsdesk

November 2, 6:02 PM

Patients treated with LUPKYNISⓇ in a repeat kidney biopsy sub-study achieved improvement in histologic activity with stable chronicity scores and no evidence of chronic injury.A propensity analysis of AURORA 1 suggested

AUPH

3 minute read

Cellectis To Present Preliminary Results Of NATHALI_01 And Updated Results Of The BALLI_01 Phases I Trials At The American Society Of Hematology 65th Annual Meeting

By Benzinga Newsdesk

November 2, 5:42 PM

Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that preliminary results of

CLLS

7 minute read

Seagen Inc. Announces New Data For ADCETRIS With Immunotherapy Combination In Hodgkin Lymphoma To Be Featured At 2023 ASH Annual Meeting, And Seagen To Unveil Novel CD30-Directed Antibody-Drug Conjugate

By Benzinga Newsdesk

November 2, 1:01 PM

– Updated Phase 2 data for ADCETRIS in combination with nivolumab in early and advanced stage classical Hodgkin lymphoma to be presented in oral session –– First preclinical data for investigational antibody-drug

SGEN